PTCT — PTC THERAPEUTICS INC
Public company
InvestorLens aggregates public filing data to show which tracked investors reported holdings in this stock. Dollar values represent reported position values, not market capitalization, and may be delayed up to 45 days. Not a recommendation.
Sourced from SEC EDGAR public filings
Why are billionaires buying PTCT?
Built from public SEC filings and public economic data. Not a recommendation.
Why? — Evidence & Confidence ▾
Of 1 tracked investors who changed their PTCT position last quarter, 0 bought and 1 sold (0% buy-side). Macro conditions are mixed for this sector (Macro Tailwind 56/100 in a Overheat regime).
- +2 tracked investors reported holding PTCT at their latest filing
- +Macro Health is 56/100 in a Overheat regime — historically acceptable for this sectorsource
- −1 tracked investor reduced or exited last quarter (0 reduced, 1 sold out)
- −13F data is disclosed up to 45 days after quarter end — positions may have changed since
- · 13F disclosure lag (up to 45 days)
- · Tracked investors are a sample, not the whole market
- · Sector regime fit is a historical average, not a guarantee
Every InvestorLens score shows its evidence — including what argues against it. Model conviction-v1 · generated 9/18/2026.
About PTC THERAPEUTICS INC (PTCT)
PTC THERAPEUTICS INC (PTCT) appears in the most recent 13F filings of 2 tracked institutional investors. The largest disclosed position is held by Ken Griffin (Citadel Advisors), valued at $108M. Across recent filings, tracked investors recorded 3 new positions, 2 increased, 0 reduced, and 3 exited. All data sourced from SEC 13F filings.
Based on recent institutional activity in PTCT
How many top investors track PTCT
Only 2 tracked investors report this position.
PTCT Ownership Composition
How PTC THERAPEUTICS INC is held across tracked investor types, based on reported 13F positions.
- Multi-Strategy / Quant100.0%
Tracked investors currently reporting PTCT
3 tracked investors have since exited this position — listed separately below.
- Ken GriffinJun 30, 2026Citadel AdvisorsShares766.8KValue$62.5M% Portfolio0.01%
- Izzy EnglanderJun 30, 2026Millennium ManagementShares46.5KValue$3.8M% Portfolio0.00%
Previously held PTCT
These investors reported PTCT in an earlier quarter but not in their most recent 13F. Figures below are their last reported position, not a current holding.
| Investor | Firm | Last reported shares | Value then | Last held |
|---|---|---|---|---|
| Steve Cohen | Point72 Asset Management | 1.1M | $85.7M | Dec 31, 2025 |
| Paul Tudor Jones | Tudor Investment Corp | 40.1K | $2M | Mar 31, 2025 |
| Ray Dalio | Bridgewater Associates | 16.2K | $1.2M | Dec 31, 2025 |
Recent activity
- New$732.6KNov 13, 2025
- Increased$1.2M(35.94%)Feb 13, 2026
- Sold$0(-100.00%)May 15, 2026
- New$21.4MNov 14, 2024
- Sold$0(-100.00%)Feb 14, 2025
- Increased$1.6M(86.70%)Aug 14, 2024
- Sold$0(-100.00%)Nov 14, 2024
- $828.3KMay 15, 2024
Frequently asked questions
- How many institutional investors hold PTCT?
- 2 tracked institutional investors disclosed a position in PTCT (PTC THERAPEUTICS INC) in their most recent 13F filing.
- Who is the largest institutional holder of PTCT?
- Ken Griffin, Citadel Advisors, holds the largest disclosed position in PTCT, valued at $108M.
- Did institutional ownership of PTCT increase or decrease?
- Across recent 13F filings, tracked investors recorded 3 new positions, 2 increased, 0 reduced, and 3 fully exited PTCT.
- Where does this PTCT ownership data come from?
- SEC Form 13F-HR filings, accessed via EDGAR. 13F filings are disclosed quarterly with a 45-day reporting delay and cover U.S.-listed long equity positions only. This is not investment advice.